Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 2Phase NA 1Phase 4 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 44Neoplasms, Plasma Cell 10Neoplasms 3Vomiting 2Recurrence 2Lung Neoplasms 2Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Nausea 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Kidney Neoplasms 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Disease 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Thalidomide × Clear all
NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

European Society for Blood and Marrow Transplantation

Phase 3 Terminated
269 enrolled 9 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT00602511 2011-02-09

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Nordic Myeloma Study Group

Phase 3 Completed
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡